KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Net Margin (2020 - 2023)

Historic Net Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 513.67%.

  • AbCellera Biologics' Net Margin fell 3749300.0% to 513.67% in Q4 2023 from the same period last year, while for Sep 2024 it was 513.67%, marking a year-over-year decrease of 2574000.0%. This contributed to the annual value of 564.83% for FY2024, which is 1798200.0% down from last year.
  • Latest data reveals that AbCellera Biologics reported Net Margin of 513.67% as of Q4 2023, which was down 3749300.0% from 433.55% recorded in Q3 2023.
  • AbCellera Biologics' 5-year Net Margin high stood at 59.7% for Q2 2020, and its period low was 513.67% during Q4 2023.
  • For the 4-year period, AbCellera Biologics' Net Margin averaged around 119.2%, with its median value being 21.77% (2020).
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 4144200bps in 2022, then crashed by -4598100bps in 2023.
  • Over the past 4 years, AbCellera Biologics' Net Margin (Quarter) stood at 56.28% in 2020, then fell by -24bps to 43.03% in 2021, then crashed by -422bps to 138.75% in 2022, then plummeted by -270bps to 513.67% in 2023.
  • Its Net Margin was 513.67% in Q4 2023, compared to 433.55% in Q3 2023 and 303.58% in Q2 2023.